Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23092873 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)
Conditions: Myelogenous Leukemia, Acute;   Leukemia, Lymphocytic, Acute;   Leukemia, Lymphoblastic, Acute, Philadelphia-Positive;   Myelogenous Leukemia, Chronic, Aggressive Phase
Interventions: Drug: SCH 900776;   Drug: Cytarabine

Indicates status has not been verified in more than two years